Top Markets
#1 Bedrock Bedrock +51.79%
#2 pippin pippin +19.58%
#3 IQ IQ +19.18%
#4 Naoris Protocol Naoris Protocol +18.03%
#5 Irys Irys +17.31%
#6 ETHGas ETHGas +16.17%
#7 Aria.AI Aria.AI +14.78%
#8 Buttcoin Buttcoin +14.36%
#9 Magma Finance Magma Finance +14.06%
#10 DUSK Network DUSK Network +11.60%
Coin of the day
Bedrock Bedrock
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rangering i aksjer #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Aksjekurs
$0.16328419
Markedsverdi
$204.14K
Endring (1 dag)
4.35%
Endring (1 år)
102.45%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategori

Healthcare
P/S-forhold for Fusion Antibodies plc (FAB)
P/S-forhold per March 2026 TTM: 9.79
Ifølge Fusion Antibodies plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 9.79. Ved slutten av 2024 hadde selskapet et P/S-forhold på 1.88.
P/S-historikk for Fusion Antibodies plc fra 2013 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 9.79 226.39%
2025 3.00 59.38%
2024 1.88 -45.47%
2023 3.45 6.43%
2022 3.24 -66.20%
2021 9.60 78.11%
2020 5.39 86.72%
2019 2.89 -54.34%
2018 6.32 -55.67%
2017 14.25 -22.61%
2016 18.42 -38.61%
2015 30.00 -20.48%
2014 37.73 -43.99%
2013 67.37 0.00%
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -63.73%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 1.13%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -44.83%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -37.31%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.90 31.71%
NL